Secondary end points included the ability of erenumab to reduce mean MMD by ≥50% from baseline at the end of the trial. At 3 months, 41.2% of patients on erenumab 140 mg achieved a 50% reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results